Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Cullinan Therapeutics, as the biotech will now be known, is switching the focus of its CD19xCD3 T-cell engager to lupus.
James Waldron
Apr 16, 2024 10:05am
Portage Biotech hints at potential closure as it halts programs
Apr 12, 2024 10:22am
Merck KGaA signs $1.4B biobuck ADC deal with Caris
Apr 4, 2024 8:25am
Prostate cancer ADC breaks FibroGen's clinical losing streak
Apr 3, 2024 10:55am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
Carisma lightens load to stretch cash runway into Q3 2025
Apr 1, 2024 11:08pm